{"id":2256,"date":"2017-08-10T18:15:08","date_gmt":"2017-08-10T12:45:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2256"},"modified":"2021-07-24T12:56:49","modified_gmt":"2021-07-24T07:26:49","slug":"the-business-cocktail-32","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32","title":{"rendered":"Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d0cc6091946\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d0cc6091946\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32\/#Loom_of_Patent_Expiry_leads_Bristol-Myers_Squibb_to_nix_58_marketing_jobs\" >Loom of Patent Expiry leads Bristol-Myers Squibb to nix 58 marketing jobs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32\/#Pfizer_commits_100M_for_a_gene_therapies_plant_in_North_Carolina\" >Pfizer commits $100M for a gene therapies plant in North Carolina<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32\/#Merck_and_GlaxoSmithKline_production_issues_lead_to_global_shortage_of_hepatitis_B_vaccine\" >Merck and GlaxoSmithKline production issues lead to global shortage of hepatitis B vaccine<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32\/#Shire_unloads_plant_to_Merck_as_it_goes_on_a_manufacturing_diet_after_buyout_splurge\" >Shire unloads plant to Merck as it goes on a manufacturing diet after buyout splurge<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Loom_of_Patent_Expiry_leads_Bristol-Myers_Squibb_to_nix_58_marketing_jobs\"><\/span>Loom of Patent Expiry leads Bristol-Myers Squibb to nix 58 marketing jobs<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p class=\"MsoNormal\" style=\"text-align: justify;\">Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs\u2014and, as a result, 58 workers will bid farewell to their jobs. The company is making changes to their HIV portfolio businessin anticipation of end-of-year generic competition, and those changes include nixing all commercial backing for the HIV lineup in the U.S. Effective Oct. 6. Six of the employees work at Bristol-Myers\u2019 Princeton Pike facility, and the other 52 are remote workers scattered across the country who report to managers located at Princeton Pike. The two meds each brought in big bucks last year, though they\u2019ve been on the decline for a few years now, thanks to new-and-improved options from field leaders Gilead Sciences and GlaxoSmithKline. Reyataz slipped below the blockbuster benchmark in 2016, churning out $912 million\u2014a dip from 2015\u2019s $1.14 billion and 2014\u2019s $1.36 billion. But it may be able to hang onto sales around the world; the brand is expected to lose exclusivity in the EU between 2017 and 2019, and it\u2019ll fend off generic competitors beginning in 2019 in Japan.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Pfizer_commits_100M_for_a_gene_therapies_plant_in_North_Carolina\"><\/span>Pfizer commits $100M for a gene therapies plant in North Carolina<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p class=\"MsoNormal\" style=\"text-align: justify;\">Pfizer committed to building a $100 million gene therapies plant in North Carolina and in exchange, North Carolina committed to providing the drugmaker with a quarter-million dollars&#8217; worth of help. Pfizer will expand an 11,000-square-foot plant in Sanford, North Carolina that it acquired last year when it bought gene therapies biotech Bamboo Therapeutics in a deal valued at up to $688 million. Bamboo bought the facility last year from the University of North Carolina about the time that Pfizer made is initial investment in the company. The drugmaker considered building a facility in Massachusetts where it has other research and manufacturing operations but decided on North Carolina where it will receive a $250,000 performance grant from the state for the project and its 40 jobs.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Merck_and_GlaxoSmithKline_production_issues_lead_to_global_shortage_of_hepatitis_B_vaccine\"><\/span>Merck and GlaxoSmithKline production issues lead to global shortage of hepatitis B vaccine<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p class=\"MsoNormal\" style=\"text-align: justify;\">A global shortage of hepatitis B vaccine has developed as both Merck &amp; Co. and GlaxoSmithKline deal with manufacturing issues, leading health agencies in England to ration use to those most at risk. Both drugmakers have acknowledged issues. Merck has had manufacturing constraints in 2017 related to the growing global demand for vaccines and unexpected demand due to lack of competitive supply. The supply interruptions for the adult formulation of RecombivaxHB began in the first quarter of 2017 and Merck does not expect to be distributing the vaccine in the United States between now and the end of 2018. A notice by the U.S. Centers for Disease Control posted last month said that GSK has sufficient supplies of adult and pediatric hepatitis B vaccines to address the anticipated gap in Merck\u2019s supply. While GSK has been able to cover for shortages in the past, the company is currently dealing with manufacturing issues of its own.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Shire_unloads_plant_to_Merck_as_it_goes_on_a_manufacturing_diet_after_buyout_splurge\"><\/span>Shire unloads plant to Merck as it goes on a manufacturing diet after buyout splurge<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">\u00a0<\/p>\n<p class=\"MsoNormal\" style=\"text-align: justify;\">Shire has found a buyer for a former Baxter vaccine plant in Europe as it continues its manufacturing consolidation after completing two big buyouts last year. Merck &amp; Co. said today that it is buying the plant in Krems an der Donau, Austria, and will immediately begin renovating the 340,000-square-foot facility, which it will use for animal vaccine production. Merck, whose animal health business was up 6% to $950 million in the second quarter, expects to be able to start production in 2022. Terms of the deal were not disclosed. Merck spokeswoman Pamela Eisele said the company estimates the site will eventually employ several hundred people and that it will begin posting available jobs immediately. Shire got the facility in its $32 billion buyout of Baxalta, which it bought last year after Baxter spun off the drug business. The plant was closed at the end of October as part of Shire\u2019s post-merger plan to cut about $700 million out of the combined operations over three years.<\/p>\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Loom of Patent Expiry leads Bristol-Myers Squibb to nix 58 marketing jobs Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs\u2014and, as a result, 58 workers will bid farewell to their jobs. The company is making changes to their HIV portfolio businessin anticipation of end-of-year generic competition, and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2122,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[784,130,173,257,1964,711,460,712,852],"industry":[17225],"therapeutic_areas":[17235,17227],"class_list":["post-2256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bms","tag-bristol-myers-squibb","tag-collaborations","tag-gene-therapies","tag-hepatitis-b","tag-ma","tag-pfizer","tag-pharma-industry","tag-shire","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK issues<\/title>\n<meta name=\"description\" content=\"Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs\u2014and, as a result, 58 workers will bid farewell to their jobs....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK issues\" \/>\n<meta property=\"og:description\" content=\"Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs\u2014and, as a result, 58 workers will bid farewell to their jobs....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-10T12:45:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"2250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK issues","description":"Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs\u2014and, as a result, 58 workers will bid farewell to their jobs....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32","og_locale":"en_US","og_type":"article","og_title":"Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK issues","og_description":"Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs\u2014and, as a result, 58 workers will bid farewell to their jobs....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-08-10T12:45:08+00:00","article_modified_time":"2021-07-24T07:26:49+00:00","og_image":[{"width":3000,"height":2250,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32","name":"Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK issues","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","datePublished":"2017-08-10T12:45:08+00:00","dateModified":"2021-07-24T07:26:49+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs\u2014and, as a result, 58 workers will bid farewell to their jobs....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-32#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma.jpg","width":"3000","height":"2250","caption":"Personalized Medicine"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09021257\/ma-300x225.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BMS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hepatitis B<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">M&amp;A<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Shire<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BMS<\/span>","<span class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapies<\/span>","<span class=\"advgb-post-tax-term\">hepatitis B<\/span>","<span class=\"advgb-post-tax-term\">M&amp;A<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">Shire<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 10, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 10, 2017 6:15 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2256"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2256\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2122"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2256"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2256"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}